- Abstract viewed - 1491 times
- PDF downloaded - 243 times
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Affiliations
Aldo Giudice
Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale – IRCCS – Naples, Italy
Anna Crispo
Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale – IRCCS – Naples, Italy
Galdiero Massimiliano
Department of Experimental Medicine II University of Naples, Italy
Giovanni D’Arena
Department of Onco- Hematology, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
Mario Felice Tecce
Department of Pharmacy, University of Salerno, Italy
Maria Grimaldi
Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale – IRCCS – Naples, Italy
Alfonso Amore
Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale – IRCCS, Naples Italy
Emanuela Esposito
Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale – IRCCS, Naples Italy
Maurizio Montella
Epidemiology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale – IRCCS – Naples, Italy
How to Cite
Metabolic Syndrome, Insulin Resistance, Circadian Disruption, Antioxidants and Pancreatic Carcinoma: an Overview
Abstract
The incidence and number of deaths caused by pancreatic tumours have been gradually rising, while the incidence and mortality of other common cancers have been declining. Risk factors for this malignant disease include cigarette smoking, family history of chronic pancreatitis, advancing age, male sex, diabetes mellitus, obesity, non-0 blood group, a high-fat diet, alcohol consumption and possibly Helicobacter pylori and hepatitis B virus infections. Metabolic diseases have become the leading cause of death in many countries. Our paper serves as a focused and updated discussion about the development of novel preventive strategies for this deadly disease.
Abbreviations. ARE: antioxidant response element; COX-2: cyclooxygenase-2; IGFs: insulin-like growthfactors; IGF1R: IGF-1 receptor; MetS: metabolic syndrome; NAFLD: non-alcoholic fatty liver disease;NAFPD: non-alcoholic fatty pancreas disease; NASH: non-alcoholic steatohepatitis; NASP: non-alcoholic steatopancreatitis; PPARγ : peroxisome proliferator-activated receptor γ; PPARs: peroxisome proliferatoractivated receptors.